Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueDepreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

Akebia Therapeutics (AKBA) Depreciation Expense (2019 - 2025)

Akebia Therapeutics (AKBA) has disclosed Depreciation Expense for 6 consecutive years, with $321000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation Expense fell 4.18% to $321000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 million, a 13.2% decrease, with the full-year FY2025 number at $1.3 million, down 13.2% from a year prior.
  • Depreciation Expense was $321000.0 for Q4 2025 at Akebia Therapeutics, up from $318000.0 in the prior quarter.
  • In the past five years, Depreciation Expense ranged from a high of $408000.0 in Q4 2022 to a low of $314000.0 in Q1 2025.
  • A 4-year average of $363384.6 and a median of $364000.0 in 2024 define the central range for Depreciation Expense.
  • Peak YoY movement for Depreciation Expense: rose 0.76% in 2024, then fell 21.0% in 2025.
  • Akebia Therapeutics' Depreciation Expense stood at $408000.0 in 2022, then decreased by 3.43% to $394000.0 in 2023, then dropped by 14.97% to $335000.0 in 2024, then decreased by 4.18% to $321000.0 in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Depreciation Expense are $321000.0 (Q4 2025), $318000.0 (Q3 2025), and $316000.0 (Q2 2025).